Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis.
Level 3 - non-randomized controlled study
Systematic review and meta-analysis of prospective observational cohort studies
PubMed 22967776 · doi:10.4088/JCP.12r07694
What was done
A systematic review and meta-analysis was conducted across MEDLINE, PsycINFO, and Cochrane databases up to June 2011 to assess the incidence and risk factors for major depressive episode (MDE) in patients receiving interferon-alpha antiviral therapy for chronic hepatitis C. Inclusion was restricted to prospective observational studies evaluating patients without a baseline DSM-IV or ICD depressive episode, diagnosed by a trained clinician. Twenty-six observational studies met the criteria. Cumulative incidence at 24 and 48 weeks and associations with baseline predictors were calculated using odds ratios and mean differences.
What was found
The cumulative incidence of treatment-induced MDE was 0.25 (95% CI, 0.16 to 0.35) at 24 weeks and 0.28 (95% CI, 0.17 to 0.42) at 48 weeks. Significant predictors of treatment-induced MDE included: - History of MDE: OR = 3.96 (95% CI, 2.52 to 6.21) - History of any psychiatric disorder: OR = 3.18 (95% CI, 1.60 to 6.32) - High baseline interleukin-6 levels: mean difference = 1.81 (95% CI, 1.09 to 2.52) - Female gender: OR = 1.40 (95% CI, 1.02 to 1.91) - Baseline subthreshold depressive symptoms: mean difference = 0.96 (95% CI, 0.31 to 1.61) - Low educational level: mean difference = -0.99 (95% CI, -1.59 to -0.39)
Why it matters
The study shows that approximately one-quarter to one-third of hepatitis C patients receiving interferon-based therapy develop clinical depression, and identifies pre-existing psychiatric history, female sex, and elevated IL-6 as key risk markers. This emphasizes the need for pre-treatment psychiatric screening and proactive monitoring during cytokine-based therapies.
Limits
Total participant sample size across the 26 included studies is not reported in the abstract. All included studies were prospective observational cohorts, leaving open the risk of residual confounding. Specific measurement units, depression scoring instruments, and heterogeneity statistics are not detailed in the abstract.
Cited by
- supports A very significant proportion of patients repeatedly administered interferon alpha for hepatitis C become clinically depressed.